Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Microb Drug Resist ; 26(6): 677-680, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31750765

RESUMO

Helicobacter pylori and non-H. pylori Helicobacter (NHPH) are associated with gastritis, ulcer, and gastric neoplasia. Because of the impossibility to culture them, diagnosis remains based on microscopic examination and molecular analysis of biopsies. Owing to the lack of data concerning antibiotic resistance of NHPH, infected patients are usually treated using antibiotics, including clarithromycin. Herein, we describe, for the first time a human infection by Helicobacter suis harboring a mutation associated to clarithromycin resistance in H. pylori. Eradication was successful with a metronidazole-based treatment. This observation highlights the benefit to use genotypic detection of resistance to improve therapeutic management of NHPH infections.


Assuntos
Antibacterianos/farmacologia , Claritromicina/farmacologia , Resistência Microbiana a Medicamentos/genética , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter heilmannii/genética , Helicobacter pylori/genética , Adulto , Feminino , Infecções por Helicobacter/tratamento farmacológico , Humanos , Metronidazol/uso terapêutico , Mutação
2.
Vet Microbiol ; 239: 108459, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31767067

RESUMO

Helicobacter suis is a fastidious, Gram negative bacterium that colonizes the stomach of pigs and non-human primates. It has also been associated with gastric disease in humans. A combined agar and broth dilution method was used to analyze the activity of 15 antimicrobial agents against 20 and 15 H. suis isolates obtained from pigs and macaques, respectively. After 48 h microaerobic incubation, minimal inhibitory concentrations (MICs) were determined by software-assisted calculation of bacterial growth as determined by quantitative real-time PCR. A monomodal distribution of MICs was seen for ß-lactam antibiotics, macrolides, gentamicin, neomycin, doxycycline, metronidazole, and rifampicin. Presence of a bimodal distribution of MICs indicated that 2 porcine isolates did not belong to the wild type population (WTP) for fluoroquinolones. This was also the case for 1 porcine isolate for tetracycline, 1 porcine and 2 primate isolates for lincomycin, and 1 primate isolate for spectinomycin. Single nucleotide polymorphisms (SNPs) were present in the gyrA gene of the isolates not belonging to the WTP for fluoroquinolones and in ribosomal protein encoding genes of the isolates not belonging to the WTP for tetracycline and spectinomycin. MICs of ampicillin, tetracycline and doxycycline were higher for porcine H. suis isolates compared to primate isolates and in these porcine isolates SNPs were detected in genes encoding penicillin binding and ribosomal proteins. This study indicates that acquired resistance occasionally occurs in H. suis isolates and that zoonotically important porcine isolates may be intrinsically less susceptible to ß-lactam antibiotics and tetracyclines than primate isolates.


Assuntos
Antibacterianos/farmacologia , Infecções por Helicobacter/microbiologia , Helicobacter heilmannii/efeitos dos fármacos , Doenças dos Macacos/microbiologia , Doenças dos Suínos/microbiologia , Animais , DNA Girase/genética , Farmacorresistência Bacteriana , Helicobacter heilmannii/isolamento & purificação , Macaca/microbiologia , Testes de Sensibilidade Microbiana , Polimorfismo de Nucleotídeo Único , Suínos/microbiologia
3.
Cancer Med ; 8(9): 4370-4379, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31210418

RESUMO

Most patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma are infected with Helicobacter pylori, and eradication therapy is the first-line treatment for localized disease with H pylori infection. However, there were several reports showing effectiveness of eradication therapy in even H pylori negative cases. Gastric MALT lymphomas are endoscopically classified into three common types: superficial, ulcerative, and elevated types. For the past 20 years, we have encountered 200 cases of localized gastric MALT lymphoma. Among them, only 4 cases (2%) showed similar macroscopic findings to those of nodular gastritis (gastric MALT lymphoma with nodular gastritis-like appearance; M-NGA). Here, we compared clinicopathological characteristics and prevalence of non-H pylori Helicobacter (NHPH) infection between M-NGA and other common types of gastric MALT lymphoma. To examine the prevalence of NHPH infection, DNA was extracted from formalin-fixed paraffin-embedded biopsy tissues from four cases of M-NGA, 20 cases of common endoscopic types of gastric MALT lymphoma, and 10 cases of nodular gastritis. We used a highly sensitive polymerase chain reaction assay to detect the presence of five species of NHPH (Helicobacter suis, H felis, H bizzozeronii, H salomonis, and H heilmannii). H suis infection was detected in 4, 2, and 0 of the 4, 20, and 10 cases of M-NGA, other types of gastric MALT lymphoma, and nodular gastritis, respectively. Other NHPH species were not detected in any cases. Complete response rate by eradication therapy was 4/4 in M-NGA cases. Therefore, nodular gastritis-like MALT lymphoma, which shows a very rare phenotype, is closely associated with NHPH infection, and eradication therapy may be the first-choice treatment.


Assuntos
Amoxicilina/uso terapêutico , Claritromicina/uso terapêutico , Gastrite/microbiologia , Infecções por Helicobacter/diagnóstico , Helicobacter heilmannii/isolamento & purificação , Lansoprazol/uso terapêutico , Linfoma de Zona Marginal Tipo Células B/microbiologia , Adulto , Amoxicilina/farmacologia , Claritromicina/farmacologia , DNA Bacteriano/genética , Quimioterapia Combinada , Gastrite/tratamento farmacológico , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/epidemiologia , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter heilmannii/genética , Humanos , Lansoprazol/farmacologia , Linfoma de Zona Marginal Tipo Células B/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Prevalência , Resultado do Tratamento
4.
Helicobacter ; 22(6)2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28834011

RESUMO

BACKGROUND: We have previously revealed that omega-3 polyunsaturated fatty acids can prevent Helicobacter pylori infection by blocking the futalosine pathway, an alternative route for menaquinone (MK) biosynthesis. MATERIALS AND METHODS: 1, Different H. pylori strains were grown in liquid media supplemented with linoleic acid, an omega-6 fatty acid, or its 10-hydroxy derivative, 10-hydroxy-cis-12-octadecenoic acid (HYA), in the presence or absence of MK. The bacterial numbers in the media were estimated by plating; 2, C57BL/6NCrl mice received drinking water supplemented with different fatty acids starting from 1 week before infection with H. pylori or Helicobacter suis until the end of the experiment. The gastric colonization levels of H. pylori or H. suis were determined 2 weeks after infection by plating or quantitative PCR, respectively; 3, Mice were given HYA, starting 1 week before infection with H. suis and continuing until 6 months after infection, for analysis of the gastric conditions. RESULTS: 1, A low concentration (20 µmol/L) of HYA in culture broth suppressed the growth of H. pylori, and this inhibition was reduced by MK supplementation; 2, HYA treatment protected mice against H. pylori or H. suis infection; 3, HYA treatment suppressed the formation of lymphoid follicles in the gastric mucus layer after H. suis infection. CONCLUSIONS: HYA prevents gastric Helicobacter infections by blocking their futalosine pathways. Daily HYA supplementation is effective for the prevention of gastric mucosa-associated lymphoid tissue lymphoma induced by persistent infection with H. suis.


Assuntos
Ácidos Graxos Ômega-6/administração & dosagem , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/prevenção & controle , Helicobacter pylori/efeitos dos fármacos , Ácidos Esteáricos/administração & dosagem , Animais , Carga Bacteriana , Contagem de Colônia Microbiana , Modelos Animais de Doenças , Feminino , Helicobacter heilmannii/efeitos dos fármacos , Camundongos Endogâmicos C57BL , Reação em Cadeia da Polimerase em Tempo Real , Resultado do Tratamento , Vitamina K 2/administração & dosagem
5.
Sci Rep ; 7(1): 1430, 2017 05 03.
Artigo em Inglês | MEDLINE | ID: mdl-28469147

RESUMO

Filamentous bulking caused by Thiothrix species is responsible for sludge washout and loss of performance in dairy wastewater treatment plants. A long-term study was conducted over 1.5 years to test three different mitigation strategies in a full-scale plant composed of two parallel sequential batch reactors (SBR1 and 2). Strategies based on polyaluminium chloride addition and volatile fatty acids reduction were ineffective to permanently solve the problem. On the contrary, modification of the reactor cycle based on the implementation of a periodic starvation proved efficient to solve the biomass wash-out and drastically reduce the sludge volume index in both reactors. Bacterial diversity analysis using 16S amplicon sequencing and quantitative PCR indicated a reduction of Thiothrix abundance from 51.9 to 1.0% in SBR1 and from 71.8 to 0.6% in SBR2. Simultaneously, the abundance of the glycogen-accumulating bacterium Candidatus Competibacter increased in both reactors. Microscopy analysis confirmed the transition between a bulking sludge towards a granular-like sludge. This study confirms the applicability of a periodic starvation to (1) solve recurring Thiothrix bulking, (2) convert loose aggregates into dense and compact granular-like structures and (3) considerably reduce energy demand for aeration.


Assuntos
Técnicas de Cultura Celular por Lotes/métodos , Esgotos/química , Thiothrix/metabolismo , Eliminação de Resíduos Líquidos/métodos , Hidróxido de Alumínio/farmacologia , Animais , Reatores Biológicos , Bovinos , Indústria de Laticínios , Ácidos Graxos Voláteis/farmacologia , Glicogênio/metabolismo , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter heilmannii/crescimento & desenvolvimento , Helicobacter heilmannii/metabolismo , Humanos , Consórcios Microbianos/efeitos dos fármacos , Consórcios Microbianos/fisiologia , RNA Ribossômico 16S/genética , Thiothrix/efeitos dos fármacos , Thiothrix/genética , Thiothrix/crescimento & desenvolvimento
6.
World J Gastroenterol ; 20(47): 17779-87, 2014 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-25548476

RESUMO

Helicobacter heilmannii sensu lato (H. heilmannii s.l.) is a group of gastric non-Helicobacter pylori Helicobacter species that are morphologically indistinguishable from each other. H. heilmannii s.l. infect the stomach of several animals and may have zoonotic potential. Although the prevalence of these infections in humans is low, they are associated with gastric pathology, including mucosa-associated lymphoid tissue lymphoma, making them a significant health issue. Here, the taxonomy, epidemiology, microbiology, diagnosis, and treatment of these infections will be reviewed. The gastric pathology associated with H. heilmannii s.l. infections in humans will also be addressed. Finally, the features of the complete bacterial genomes available and studies on species-specific pathogenesis will be reviewed. The understanding of the mechanisms that underlie gastric disease development mediated by the different bacterial species that constitute H. heilmannii s.l. is essential for developing strategies for prevention and treatment of these infections.


Assuntos
Infecções por Helicobacter/microbiologia , Helicobacter heilmannii/patogenicidade , Gastropatias/microbiologia , Estômago/microbiologia , Animais , Antibacterianos/uso terapêutico , Quimioterapia Combinada , Genoma Bacteriano , Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/epidemiologia , Infecções por Helicobacter/transmissão , Helicobacter heilmannii/classificação , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter heilmannii/genética , Interações Hospedeiro-Patógeno , Humanos , Inibidores da Bomba de Prótons/uso terapêutico , Estômago/efeitos dos fármacos , Estômago/patologia , Gastropatias/diagnóstico , Gastropatias/tratamento farmacológico , Gastropatias/epidemiologia , Resultado do Tratamento
7.
PLoS One ; 7(11): e47396, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23209550

RESUMO

microRNAs (miRNAs) are small non-coding RNAs that can function as endogenous silencers of target genes and play critical roles in human malignancies. To investigate the molecular pathogenesis of gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the miRNA expression profile was analyzed. miRNA microarray analysis with tissue specimens from gastric MALT lymphomas and surrounding non-tumor mucosae revealed that a hematopoietic-specific miRNA miR-142 and an oncogenic miRNA miR-155 were overexpressed in MALT lymphoma lesions. The expression levels of miR-142-5p and miR-155 were significantly increased in MALT lymphomas which do not respond to Helicobacter pylori (H. pylori) eradication. The expression levels of miR-142-5p and miR-155 were associated with the clinical courses of gastric MALT lymphoma cases. Overexpression of miR-142-5p and miR-155 was also observed in Helicobacter heilmannii-infected C57BL/6 mice, an animal model of gastric MALT lymphoma. In addition, miR-142-5p and miR-155 suppress the proapoptotic gene TP53INP1 as their target. The results of this study indicate that overexpression of miR-142-5p and miR-155 plays a critical role in the pathogenesis of gastric MALT lymphoma. These miRNAs might have potential application as therapeutic targets and novel biomarkers for gastric MALT lymphoma.


Assuntos
Linfoma de Zona Marginal Tipo Células B/genética , MicroRNAs/genética , Neoplasias Gástricas/genética , Adulto , Idoso , Animais , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Sequência de Bases , Biomarcadores Tumorais , Proteína C-Reativa/genética , Modelos Animais de Doenças , Feminino , Mucosa Gástrica/metabolismo , Mucosa Gástrica/microbiologia , Mucosa Gástrica/patologia , Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Infecções por Helicobacter/tratamento farmacológico , Helicobacter heilmannii/efeitos dos fármacos , Humanos , Masculino , Camundongos , MicroRNAs/química , Pessoa de Meia-Idade , Dados de Sequência Molecular , Proteínas do Tecido Nervoso/genética , Proteínas de Fusão Oncogênica/genética , Translocação Genética , Proteína Supressora de Tumor p53/genética
8.
Vet Microbiol ; 153(3-4): 339-42, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-21733643

RESUMO

Helicobacter suis is a very fastidious porcine gastric pathogen, which is also considered to be of zoonotic importance. In vitro antimicrobial susceptibility cannot be determined using standard assays, as this agent only grows in a biphasic medium with an acidic pH. Therefore, a combined agar and broth dilution method was used to analyse the activity of nine antimicrobial agents against nine H. suis isolates. After 48 h microaerobic incubation, minimal inhibitory concentrations (MICs) were determined by software-assisted calculation of bacterial growth. Only for enrofloxacin a bimodal distribution of MICs was demonstrated, indicating acquired resistance in one strain, which showed an AGT→AGG (Ser→Arg) substitution at codon 99 of gyrA. In conclusion, the assay developed here is suitable for determination of the antimicrobial susceptibility of H. suis isolates, although activity of acid sensitive antimicrobial agents may be higher than predicted from MIC endpoints.


Assuntos
Anti-Infecciosos/farmacologia , Helicobacter heilmannii/efeitos dos fármacos , Animais , Farmacorresistência Bacteriana , Enrofloxacina , Fluoroquinolonas/farmacologia , Helicobacter heilmannii/genética , Helicobacter heilmannii/isolamento & purificação , Testes de Sensibilidade Microbiana , Suínos
11.
Vaccine ; 24(14): 2469-76, 2006 Mar 24.
Artigo em Inglês | MEDLINE | ID: mdl-16423431

RESUMO

"Helicobacter (H.) heilmannii" type 1 colonizes the human stomach. It has been shown to be identical to "Candidatus H. suis", a Helicobacter species colonizing the stomach of more than 60% of slaughter pigs. This bacterium is, until now, not isolated in vitro. The effect of vaccination on "Candidatus H. suis" infection was studied in a mouse model. Mice were vaccinated intranasally or subcutaneously with whole bacterial cell lysate of Helicobacter pylori or Helicobacter felis and subsequently challenge infected with "Candidatus H. suis". Intranasal and subcutaneous immunisation caused a decrease in faecal excretion of "Candidatus H. suis" DNA. Urease tests on stomach tissue samples at 16 weeks after challenge infection were negative in all H. felis intranasally immunized animals and in the majority of the animals of the other immunisation groups. Since PCR on stomach tissue samples at 16 weeks after challenge infection could still detect "Candidatus H. suis DNA" in all immunisation-challenge groups, complete clearance of challenge bacteria was not achieved.


Assuntos
Antígenos Heterófilos/administração & dosagem , Vacinas Bacterianas/administração & dosagem , Infecções por Helicobacter/prevenção & controle , Helicobacter felis/química , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter pylori/química , Administração Intranasal , Animais , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/imunologia , Antígenos Heterófilos/imunologia , Vacinas Bacterianas/imunologia , DNA Bacteriano/análise , Helicobacter heilmannii/metabolismo , Imunização , Injeções Subcutâneas , Camundongos , Camundongos Endogâmicos BALB C , Reação em Cadeia da Polimerase
12.
Antimicrob Agents Chemother ; 49(11): 4530-5, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16251292

RESUMO

"Helicobacter heilmannii" (proposed name) type 1 colonizes the human stomach. It has been shown to be identical to "Candidatus Helicobacter suis," a Helicobacter species colonizing the stomachs of >60% of slaughter pigs. This bacterium has not been isolated in vitro until now. Antibiotic susceptibility testing of "Candidatus Helicobacter suis" has not been carried out so far. For the present study, a mouse model was adopted to evaluate the antibiotic susceptibility of this organism. Mice infected with "Candidatus Helicobacter suis" were treated with amoxicillin and omeprazole, a therapy which is used to treat H. heilmannii infections in humans. Two different isolates of "Candidatus Helicobacter suis" were tested. The excretion of bacterial DNA was assessed during treatment, using PCR on fecal samples. At the end of the experiment, 8 days after the cessation of treatment, the presence of infection was evaluated using a urease test and a PCR test on stomach samples. A marked decrease in the excretion of bacterial DNA was observed a few days after the onset of treatment, and the level remained low until the end of the experiment. A difference in susceptibility between the two "Candidatus Helicobacter suis" isolates was pointed out. The in vivo mouse model infected with "Candidatus Helicobacter suis" will be useful for further screening of potential therapeutic regimens.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Helicobacter/tratamento farmacológico , Helicobacter heilmannii/efeitos dos fármacos , Amoxicilina/uso terapêutico , Animais , DNA Bacteriano/análise , Modelos Animais de Doenças , Fezes/microbiologia , Infecções por Helicobacter/microbiologia , Imuno-Histoquímica , Camundongos , Camundongos Endogâmicos BALB C , Reação em Cadeia da Polimerase , Estômago/microbiologia
13.
Pathol Int ; 55(7): 398-404, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15982214

RESUMO

Gastric biopsy materials of 4074 consecutive Japanese patients undergoing esophagogastroduodenoscopy were reviewed, along with those of 15 patients with Helicobacter heilmannii infection (11, chronic gastritis; four, mucosa-associated lymphoid tissue (MALT) lymphoma). In four patients with H. heilmannii infection, the materials were examined by transmission electronmicroscopy. Urea breath test (three patients) and antibody test (five patients) were performed in patients with H. heilmannii infection. In two patients with MALT lymphoma, H. heilmannii was eradicated. The prevalence of H. heilmannii was 0.1% in the consecutive series. In chronic gastritis, the gastric mucosa was endoscopically normal (13.3%), had erythema (33.3%), or had erosions (53.3%); histologically, it showed no epithelial change, mild mononuclear cell infiltration, and slight and focal neutrophil infiltration; Helicobacter heilmannii was positive with anti-H. pylori antibody, and was detected in the mucous gel layer and in foveolae. In MALT lymphoma, the gastric mucosa was coarsely granular with enlarged mucosal folds without ulcers (two cases), with small ulcers (one case), or with multiple erosions (one case). Urea breath test and antibody test were both negative. Eradication of H. heilmannii resulted in remission of MALT lymphoma. Helicobacter heilmannii infection is therefore uncommon in Japanese adults, but is associated with chronic gastritis and gastric MALT lymphoma.


Assuntos
Infecções por Helicobacter/patologia , Helicobacter heilmannii , Omeprazol/análogos & derivados , 2-Piridinilmetilsulfinilbenzimidazóis , Adulto , Idoso , Amoxicilina/uso terapêutico , Anti-Infecciosos/uso terapêutico , Claritromicina/uso terapêutico , Endoscopia Gastrointestinal , Feminino , Gastrite/complicações , Infecções por Helicobacter/complicações , Infecções por Helicobacter/tratamento farmacológico , Helicobacter heilmannii/efeitos dos fármacos , Humanos , Japão , Lansoprazol , Linfoma de Zona Marginal Tipo Células B/complicações , Masculino , Microscopia Eletrônica de Transmissão , Pessoa de Meia-Idade , Omeprazol/uso terapêutico , Estômago/efeitos dos fármacos , Estômago/microbiologia , Estômago/ultraestrutura , Resultado do Tratamento
14.
J Biomol Screen ; 10(3): 235-45, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15809319

RESUMO

A microelectronic array assay was developed to specifically genotype Helicobacter pylori versus Helicobacter heilmannii and to determine antimicrobial resistance. Helicobacter 16S rRNA and 23S rRNA genes were specifically generated with Helicobacter genus-specific primers, respectively. The single-nucleotide polymorphisms (SNPs) in 16S rRNA, 268T specific in the H. pylori sequence, and 263A specific in H. heilmannii were used as molecular markers for identification of H. pylori and H. heilmannii, respectively. A triple-base-pair resistant mutation, AGA965-967TTC in 16S rRNA, is known to be responsible for H. pylori tetracycline resistance and was detected to identify resistant strains. H. pylori macrolide resistance was determined by the identification of 3 defined mutations in the 23S rRNA gene using the same method. The assay could be directly used to detect H. pylori in feces. The assay performs multiple determinations, including identification of Helicobacter species and antibiotic resistances, on the same microelectronic platform and is highly amenable to the development of other DNA-based assays.


Assuntos
Helicobacter heilmannii/isolamento & purificação , Helicobacter pylori/isolamento & purificação , Testes de Sensibilidade Microbiana , Análise de Sequência com Séries de Oligonucleotídeos/métodos , Resistência a Tetraciclina , Sequência de Bases , Eletroforese , Fezes/microbiologia , Genótipo , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter heilmannii/genética , Helicobacter pylori/efeitos dos fármacos , Helicobacter pylori/genética , Dados de Sequência Molecular , Mutação , Polimorfismo de Nucleotídeo Único , RNA Ribossômico 16S/genética , RNA Ribossômico 23S/genética , Resistência a Tetraciclina/genética
15.
Acta Paediatr ; 93(5): 707-9, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15174799

RESUMO

AIM: To evaluate the occurrence and clinical characteristics of Helicobacter heilmannii infection among children presenting with dyspeptic symptoms. METHOD: Prospective cohort study of 580 patients. RESULTS: Of all examined dyspeptic children, 26.4% were infected with spiral-shaped organisms, and 0.9% of patients were found to be infected with spiral H. heilmannii-like organisms. CONCLUSION: In children with dyspeptic symptoms, the possible presence of gastroduodenal disease due to H. heilmannii should be considered. Further studies are needed to clarify H. heilmannii-related gastroduodenal pathology in the paediatric population.


Assuntos
Gastroenteropatias/diagnóstico , Infecções por Helicobacter/diagnóstico , Helicobacter heilmannii/isolamento & purificação , Adolescente , Antibacterianos/uso terapêutico , Estudos de Coortes , República Tcheca/epidemiologia , Feminino , Gastroenteropatias/tratamento farmacológico , Gastroenteropatias/epidemiologia , Infecções por Helicobacter/tratamento farmacológico , Infecções por Helicobacter/epidemiologia , Helicobacter heilmannii/efeitos dos fármacos , Helicobacter pylori/efeitos dos fármacos , Helicobacter pylori/isolamento & purificação , Humanos , Masculino , Prevalência , Estudos Prospectivos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...